NeoGenomics (NEO) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. BROS
5. FIS
6. DDOG
7. QCOM
8. EW
9. ZG
10. W

Go back to NeoGenomics (NEO) Tops Q2 EPS by 1c

NeoGenomics Reports 18% Revenue Growth and Strong Gains in Adjusted EBITDA

July 23, 2015 7:01 AM EDT

FT. MYERS, Fla., July 23, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2015.

Second Quarter 2015 Highlights:

18% increase in consolidated revenue 9% growth in base(1) revenue despite $2.1 million reduction in FISH reimbursement 21% growth in base(1) test volume despite FISH insourcing by one large client Record low $215 Avg Cost per Test in base(1) business 300 basis point expansion in gross margin from 41.4% in... More